Fleischer Alan B, Boguniewicz Mark
Department of Dermatology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA.
J Drugs Dermatol. 2010 May;9(5):488-98.
Persistent pruritus, or itch, is one of the earliest symptoms of atopic dermatitis (AD). When pruritus is untreated, the incessant scratching response by the patient can increase the inflammatory response, resulting in aggravation of disease symptoms and severity, increasing flares and worsening patient quality of life. Therefore, it is essential that pruritus be treated effectively, rapidly and safely for optimal management of AD. In this article, the authors review clinical trials using tacrolimus ointment, a topical calcineurin inhibitor, to treat adult and pediatric patients with AD over a wide range of disease severity focusing on its efficacy in rapidly reducing pruritus. Furthermore, the authors evaluate trials in which tacrolimus ointment was directly compared with topical corticosteroids, the mainstay of AD treatment, and pimecrolimus cream, another topical calcineurin inhibitor, as well as long-term safety trials in which patients applied tacrolimus ointment for extended periods.
持续性瘙痒是特应性皮炎（AD）最早出现的症状之一。若瘙痒未得到治疗，患者持续不断的搔抓反应会加重炎症反应，导致疾病症状和严重程度加剧，发作频率增加，患者生活质量恶化。因此，为了对AD进行最佳管理，必须有效、快速且安全地治疗瘙痒。在本文中，作者回顾了使用他克莫司软膏（一种局部钙调神经磷酸酶抑制剂）治疗不同疾病严重程度的成人和儿童AD患者的临床试验，重点关注其在快速减轻瘙痒方面的疗效。此外，作者评估了将他克莫司软膏与AD治疗的主要药物局部糖皮质激素以及另一种局部钙调神经磷酸酶抑制剂吡美莫司乳膏直接进行比较的试验，以及患者长期使用他克莫司软膏的长期安全性试验。
